SHPMF (Shanghai Pharmaceuticals Holding Co) Piotroski F-Score: 7 (As of Jul. 01, 2026) — 40% Above Median


SHPMF Shanghai Pharmaceuticals Holding Co Ltd SHPMF
77 GF Score
Price $1.46
GF Value $1.89
! 4 Warning Signs
View Full Analysis

What is Shanghai Pharmaceuticals Holding Co Piotroski F-Score?

Shanghai Pharmaceuticals Holding Co SHPMF -4.58% 77 Piotroski F-Score is 7 as of Jul. 01, 2026, which is 40% above its 10-year median of 5.00. GuruFocus rates SHPMF with a GF Score™ of 77/100 and a GF Value™ of $1.89. The stock has 4 warning signs investors should review. Among 112 Medical Distribution companies, Shanghai Pharmaceuticals Holding Co ranks better than 89.29% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanghai Pharmaceuticals Holding Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Shanghai Pharmaceuticals Holding Co's Piotroski F-Score or its related term are showing as below:

SHPMF' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 7
Current: 7

During the past 13 years, the highest Piotroski F-Score of Shanghai Pharmaceuticals Holding Co was 7. The lowest was 2. And the median was 5.

Shanghai Pharmaceuticals Holding Co  (OTCPK:SHPMF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Shanghai Pharmaceuticals Holding Co Piotroski F-Score Related Terms


Shanghai Pharmaceuticals Holding Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Shanghai Pharmaceuticals Holding Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Pharmaceuticals Holding Co Piotroski F-Score Chart

Shanghai Pharmaceuticals Holding Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 5.00 5.00 6.00 5.00

Shanghai Pharmaceuticals Holding Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 7.00 5.00 5.00 7.00

SHPMF vs MCK, CAH, COR: Piotroski F-Score Comparison

For the Medical Distribution subindustry, Shanghai Pharmaceuticals Holding Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Pharmaceuticals Holding Co Piotroski F-Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Shanghai Pharmaceuticals Holding Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Shanghai Pharmaceuticals Holding Co's Piotroski F-Score falls into.


SHPMF
77GF Score
Shanghai Pharmaceuticals Holding Co Ltd SHPMF
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 435.323 + 96.61 + 81.993 + 205.708 = $820 Mil.
Cash Flow from Operations was 444.763 + 190.995 + 540.151 + -146.5 = $1,029 Mil.
Revenue was 9864.39 + 10315.077 + 9726.739 + 10920 = $40,826 Mil.
Gross Profit was 1069.073 + 1051.024 + 1135.391 + 1174.227 = $4,430 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(31157.752 + 33155.125 + 33234.54 + 33102.676 + 34150.619) / 5 = $32960.1424 Mil.
Total Assets at the begining of this year (Mar25) was $31,158 Mil.
Long-Term Debt & Capital Lease Obligation was $685 Mil.
Total Current Assets was $26,529 Mil.
Total Current Liabilities was $19,807 Mil.
Net Income was 192.928 + 157.189 + 68.448 + 183.889 = $602 Mil.

Revenue was 9546.964 + 9923.062 + 9013.172 + 9761.29 = $38,244 Mil.
Gross Profit was 1122.027 + 990.544 + 1023.885 + 1000.973 = $4,137 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(30190.51 + 30509.307 + 31619.749 + 30382.989 + 31157.752) / 5 = $30772.0614 Mil.
Total Assets at the begining of last year (Mar24) was $30,191 Mil.
Long-Term Debt & Capital Lease Obligation was $1,115 Mil.
Total Current Assets was $24,459 Mil.
Total Current Liabilities was $18,045 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanghai Pharmaceuticals Holding Co's current Net Income (TTM) was 820. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanghai Pharmaceuticals Holding Co's current Cash Flow from Operations (TTM) was 1,029. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=819.634/31157.752
=0.02630594

ROA (Last Year)=Net Income/Total Assets (Mar24)
=602.454/30190.51
=0.01995508

Shanghai Pharmaceuticals Holding Co's return on assets of this year was 0.02630594. Shanghai Pharmaceuticals Holding Co's return on assets of last year was 0.01995508. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Shanghai Pharmaceuticals Holding Co's current Net Income (TTM) was 820. Shanghai Pharmaceuticals Holding Co's current Cash Flow from Operations (TTM) was 1,029. ==> 1,029 > 820 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=684.813/32960.1424
=0.020777

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=1114.927/30772.0614
=0.03623179

Shanghai Pharmaceuticals Holding Co's gearing of this year was 0.020777. Shanghai Pharmaceuticals Holding Co's gearing of last year was 0.03623179. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=26529.134/19806.537
=1.33941304

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=24459.148/18044.933
=1.35545796

Shanghai Pharmaceuticals Holding Co's current ratio of this year was 1.33941304. Shanghai Pharmaceuticals Holding Co's current ratio of last year was 1.35545796. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Shanghai Pharmaceuticals Holding Co's number of shares in issue this year was 3730.94. Shanghai Pharmaceuticals Holding Co's number of shares in issue last year was 3702.973. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=4429.715/40826.206
=0.10850175

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=4137.429/38244.488
=0.10818367

Shanghai Pharmaceuticals Holding Co's gross margin of this year was 0.10850175. Shanghai Pharmaceuticals Holding Co's gross margin of last year was 0.10818367. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=40826.206/31157.752
=1.31030653

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=38244.488/30190.51
=1.26677184

Shanghai Pharmaceuticals Holding Co's asset turnover of this year was 1.31030653. Shanghai Pharmaceuticals Holding Co's asset turnover of last year was 1.26677184. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+0+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanghai Pharmaceuticals Holding Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
Shanghai Pharmaceuticals Holding Co (SHPMF) has a Piotroski F-Score of 7 as of Jul. 01, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. This is 40% above median its historical median of 5.00. Over the past decade, Shanghai Pharmaceuticals Holding Co's Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #12 out of 112 companies in the Medical Distribution industry, placing it in the top 10.7%.
Is Shanghai Pharmaceuticals Holding Co's Piotroski F-Score too high?
Shanghai Pharmaceuticals Holding Co's current Piotroski F-Score of 7 is 40% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Medical Distribution industry median Piotroski F-Score is 5.00. Shanghai Pharmaceuticals Holding Co's value of 7 is 40% above this industry median. Based on the distribution chart, Shanghai Pharmaceuticals Holding Co ranks #12 out of 112 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Pharmaceuticals Holding Co has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Pharmaceuticals Holding Co's Piotroski F-Score compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #12 out of 112 companies for Piotroski F-Score. This places Shanghai Pharmaceuticals Holding Co in the top 11% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Shanghai Pharmaceuticals Holding Co's value of 7 is 40% above this benchmark. Historically, Shanghai Pharmaceuticals Holding Co's own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Shanghai Pharmaceuticals Holding Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Distribution company?
The median Piotroski F-Score among Medical Distribution companies is 5.00, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Pharmaceuticals Holding Co's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. For the Medical Distribution industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Pharmaceuticals Holding Co's current Piotroski F-Score is 7, which is 40% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Pharmaceuticals Holding Co stock overvalued right now?
Shanghai Pharmaceuticals Holding Co (SHPMF) has a current Piotroski F-Score of 7. The stock's GF Value™ is $1.89, compared to a current price of $1.46 — trading 22.8% below its estimated fair value. The current Piotroski F-Score is 7, which is 40% above median its 10-year median of 5.00 and 40% above the Medical Distribution industry median of 5.00. Shanghai Pharmaceuticals Holding Co's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Shanghai Pharmaceuticals Holding Co (SHPMF), the current Piotroski F-Score is 7 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Pharmaceuticals Holding Co (SHPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co stock appears to be undervalued. The current stock price of $1.46 is trading 22.8% below its estimated GF Value™ of $1.89.

Key valuation signals for SHPMF:

  • Piotroski F-Score: 7 (40% above median its 10-year median of 5.00)
  • GF Value™: $1.89 vs. price of $1.46 (22.8% below fair value)
  • GF Score™: 77/100 with 4 warning signs
  • Industry Position: 40% above the Medical Distribution median (#12 of 112)

No single metric tells the full story. See the SHPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai Pharmaceuticals Holding Co Business Description

Address No. 200 Taicang Road, Shanghai Pharmaceutical Building, Shanghai, CHN, 200020
Shanghai Pharmaceuticals Holding Co Ltd is engaged in the pharmaceutical drug development and distribution business. The Group's reportable segments are: Production, Distribution, Retail, and Other. The majority of its revenue comes from the Distribution segment, which is mainly engaged in distribution, warehousing, and other value-added pharmaceutical supply chain solutions and related services for pharmaceutical manufacturers and dispensers. The Retail segment operates a network of retail pharmacy stores, and the Production segment is mainly engaged in research and development, production, and sales of a broad range of pharmaceutical and healthcare products. Geographically, the Group mainly operates in the People's Republic of China (PRC).
77GF Score

Get the complete analysis for SHPMF

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.46
Price
$1.89
GF Value